Cellular Intelligence hires neurologist to assess Novo Nordisk's Parkinson's stem cell program
read at Endpoints ↗DealNeutral
Cellular Intelligence, an AI‑driven biotech, announced it is evaluating Novo Nordisk's Parkinson's stem cell therapy after Novo shut down its cell therapy unit.
The company engaged neurologist and drug developer Nuno Mendonça to perform due diligence on the program, reviewing the data that originally guided Novo's development.
The move signals continued interest in cell‑based treatments for Parkinson’s disease, with Cellular Intelligence seeking to potentially acquire or partner on the therapy.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “The data that led Cellular Intelligence to pick up Novo's Parkinson's stem cell therapy”
read at Endpoints ↗89 words · retrieved Jul 10
comments(0)
5-min edit window · permanent after that